Continuous Prostanoid Initiation in Severe Pulmonary Hypertension in the Pediatric Cardiac Intensive Care Unit

Objective Limited data exists regarding prostanoid (PGI2) use in critically ill patients with pulmonary hypertension. (PH) in the pediatric cardiac intensive care unit (CICU) setting. Materials and Methods Single center, retrospective study of patients with diagnosis of PH who received continuous PG...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric cardiology 2024-12, Vol.45 (8), p.1798-1803
Main Authors: Garcia, Richard U., Beshish, Asaad, Butto, Arene, Kanaan, Usama, Maher, Kevin
Format: Article
Language:English
Subjects:
Adolescent
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - therapeutic use
Cardiac Surgery
Cardiology
Child
Child, Preschool
Epoprostenol - administration & dosage
Epoprostenol - analogs & derivatives
Epoprostenol - therapeutic use
Female
Humans
Hypertension, Pulmonary - drug therapy
Infant
Infant, Newborn
Intensive Care Units, Pediatric
Male
Medicine
Medicine & Public Health
Retrospective Studies
Vascular Surgery
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Limited data exists regarding prostanoid (PGI2) use in critically ill patients with pulmonary hypertension. (PH) in the pediatric cardiac intensive care unit (CICU) setting. Materials and Methods Single center, retrospective study of patients with diagnosis of PH who received continuous PGI2 and were admitted to CICU from January/2015 to April/2022. Data collected included patient demographics and clinical characteristics including diagnosis, etiology of PH, vasoactive and ventilatory support, length of stay, and survival. Type, initial, maximum, and final dose of PGI2 as well as hemodynamic data was obtained. Data reported as mean ± standard deviation. Significance taken p value 
ISSN:0172-0643
1432-1971
1432-1971
DOI:10.1007/s00246-023-03282-y